Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
As of today, Eli Lilly(LLY) shares are valued at $1,176.75. The company's market cap stands at 1.11T, with a P/E ratio of 42.09 and a dividend yield of 0.55%.
During the trading session on 2026-07-18, Eli Lilly(LLY) shares reached a daily high of $1,187.95 and a low of $1,154.33. At a current price of $1,176.75, the stock is +1.9% higher than the low and still -0.9% under the high.
Trading volume for Eli Lilly(LLY) stock has reached 2.76M, versus its average volume of 2.48M.
The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.
The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.
LLY News
Key Points Eli Lilly's growth is being driven by its GLP-1 drugs right now. Mounjaro and Zepbound accounted for nearly two-thirds of the drug maker's first-qu...
Key Points Novo Nordisk is pulling ahead of Eli Lilly in the market for oral weight loss medicines. Eli Lilly has several tricks up its sleeve that could help...
george frey / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....
Analyst ratings
81%
of 31 ratingsMore LLY News
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of...
Eli Lilly (NYSE:LLY) has agreed to acquire AtaiBeckley, a clinical-stage company focused on psychedelic-based mental health therapies. The transaction expands...
Eli Lilly has signed a definitive agreement to acquire psychedelic drug developer AtaiBeckley (NasdaqGM:ATAI). The deal includes upfront cash plus contingent v...
The Eli Lilly move on AtaiBeckley has pushed psychedelics and mental health treatments back into the spotlight, and it is giving investors fresh reasons to reas...
Key Points AtaiBeckley is developing a promising depression treatment. Eli Lilly has long been a leader in neuroscience. The two companies want to work toget...
AtaiBeckley (NASDAQ:ATAI), a clinical-stage mental health and psychedelic drug developer, closed at $7.15, up 33.4%. Eli Lilly’s (NYSE:LLY) announced acquisitio...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.